rs121908664
Variant summary
Our verdict is Pathogenic. Variant got 19 ACMG points: 19P and 0B. PM1PM2PM5PP2PP3_StrongPP5_Very_Strong
The NM_002335.4(LRP5):c.1481G>A(p.Arg494Gln) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000274 in 1,461,890 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R494W) has been classified as Likely pathogenic.
Frequency
Consequence
NM_002335.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 19 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
LRP5 | NM_002335.4 | c.1481G>A | p.Arg494Gln | missense_variant | 7/23 | ENST00000294304.12 | NP_002326.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
LRP5 | ENST00000294304.12 | c.1481G>A | p.Arg494Gln | missense_variant | 7/23 | 1 | NM_002335.4 | ENSP00000294304 | P1 | |
LRP5 | ENST00000529993.5 | c.1412+3237G>A | intron_variant, NMD_transcript_variant | 1 | ENSP00000436652 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome AF: 0.00000274 AC: 4AN: 1461890Hom.: 0 Cov.: 32 AF XY: 0.00000275 AC XY: 2AN XY: 727248
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 03, 2022 | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 494 of the LRP5 protein (p.Arg494Gln). This variant is not present in population databases (gnomAD no frequency). For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Arg494 amino acid residue in LRP5. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 30452590; Invitae). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Experimental studies have shown that this missense change affects LRP5 function (PMID: 21528003, 28420620). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt LRP5 protein function. ClinVar contains an entry for this variant (Variation ID: 6274). This missense change has been observed in individuals with autosomal dominant familial exudative vitreoretinopathy and autosomal recessive osteoporosis-pseudoglioma syndrome (PMID: 11719191, 28420620, 35106624). - |
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Aug 23, 2022 | Published functional studies demonstrate a damaging effect: affects Wnt1 signaling (Bhat 2007); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Not observed at significant frequency in large population cohorts (Lek 2006).; This variant is associated with the following publications: (PMID: 28420620, 11719191, 15143163, 16252235, 31827910, 30452590, 34426522, 16390319, 35106624, 21528003, 27535533, 17276019) - |
Osteoporosis with pseudoglioma Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Nov 16, 2001 | - - |
LRP5-related disorder Pathogenic:1
Likely pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jun 02, 2024 | The LRP5 c.1481G>A variant is predicted to result in the amino acid substitution p.Arg494Gln. This variant was reported in a study of patients with familial exudative vitreoretinopathy (FEVR) and functional studies showed that this variant lead to defective signaling (cited in the abstract of Liu et al. 2017. PubMed ID: 28420620). This variant was also reported in association with osteoporosis-pseudoglioma syndrome and noted to lead to a decrease in Wnt signaling; however, clinical and functional evidence was not provided in these studies to further assess the pathogenicity of this variant (Figure 2A, Gong et al. 2001. PubMed ID: 11719191; Mao et al. 2011. PubMed ID: 21528003). This variant has not been reported in a large population database, indicating this variant is rare. This variant has been interpreted as pathogenic or likely pathogenic by multiple submitters in the ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/variation/6274). In addition, another variant impacting the same amino acid residue (p.Arg494Trp) has been reported in patients with familial exudative vitreoretinopathy (Table 6, Li et al. 2018. PubMed ID: 30452590; Family No. 12 in Wang et al. 2021. PubMed ID: 34526760). Note the family in Wang et al. had additional variants in LRP5 and KIF11. Based on this evidence, we interpret the c.1481G>A (p.Arg494Gln) variant as likely pathogenic. - |
Osteoporosis;C0432252:Osteoporosis with pseudoglioma;C0432273:Worth disease;C1843330:Autosomal dominant osteopetrosis 1;C1851402:Exudative vitreoretinopathy 1;C1866079:Bone mineral density quantitative trait locus 1;C1866176:Exudative vitreoretinopathy 4;C4693479:Polycystic liver disease 4 with or without kidney cysts Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Mar 07, 2022 | - - |
Exudative vitreoretinopathy 1 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Mendelics | May 04, 2022 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at